Trillium Therapeutics Inc. ('Trillium' or the 'Company') announced that Paul Walker has been appointed to the company’s Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020. Mr. Walker and Dr. Behbahani are general partners with New Enterprise Associates (NEA). Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Dr. Behbahani’s previous positions include a consultant in business development at The Medicines Company. The company also announced that Dr. Robert Uger, Trillium’s Chief Scientific Officer has resigned from the Board of Directors effective February 6, 2020.